Annuncio • Jan 26
Microsaic Systems plc (AIM:MSYS) acquired certain assets of DeepVerge plc and certain assets of Innovenn Limited from DeepVerge plc and Innovenn Limited for £0.1 million. Microsaic Systems plc (AIM:MSYS) announced the acquisition of certain assets of DeepVerge plc and certain assets of Innovenn Limited from DeepVerge plc and Innovenn Limited for £0.1 million on January 12, 2024. Completion is subject to various conditions including Admission and the delivery of several intellectual property assignments to the benefit of the Company by no later than January 24, 2024. Aubrey Powell, Angus Campbell and Oliver Platts of Singer Capital Markets Limited acted as financial advisor to Microsaic Systems plc. Andy Thacker and James Pope of Turner Pope Investments (TPI) Limited acted as joint broker in the transaction.Microsaic Systems plc (AIM:MSYS) completed the acquisition of certain assets of DeepVerge plc and certain assets of Innovenn Limited from DeepVerge plc and Innovenn Limited on January 25, 2024. Annuncio • Jan 16
Microsaic Systems plc (AIM:MSYS) announced the acquisition of certain assets of DeepVerge plc and certain assets of Innovenn Limited from DeepVerge plc and Innovenn Limited for £0.1 million. Microsaic Systems plc (AIM:MSYS) announced the acquisition of certain assets of DeepVerge plc and certain assets of Innovenn Limited from DeepVerge plc and Innovenn Limited for £0.1? million on January, 12 2024. Completion is subject to various conditions including Admission and the delivery of several intellectual property assignments to the benefit of the Company by no later than January, 24 2024. Annuncio • Dec 16
DeepVerge Announces Cancellation of Admission of its Shares to Trading on AIM, Effective 27 December 2023 The board of DeepVerge plc provided an update to shareholders, further to the previous notification on 14 September 2023, the board has made progress with potential buyers of certain assets and intellectual property owned within the Modern Water and Labskin business units and hopes to be able to agree terms for the sale of these various assets during the next month. Further to the notification of 26 June 2023, DeepVerge plc, the holding company which neither trades nor has operating revenues, currently has around £0.3 million of net liabilities. Given the situation referred to above, uncertainty remains as to whether the company will have sufficient funds to pay its debts as they fall due. The cancellation of the admission of the company's shares to trading on AIM (‘Cancellation’) is expected therefore to take place with effect from 7.00 a.m. on 27 December 2023. Annuncio • Aug 08
Tony Ryan and Michael Fitzgerald, Current management and previous owners of Glanaco acquired Glanaco Limited from DeepVerge plc (AIM:DVRG) for €1. Tony Ryan and Michael Fitzgerald, Current management and previous owners of Glanaco acquired Glanaco Limited from DeepVerge plc (AIM:DVRG) for €1 on August 7, 2023. For the year ended December 31, 2022 Glanaco has loss before tax of €0.075 million, turnover of €1.74 million and (unaudited) net liabilities amounted to €0.042 million. SPARK Advisory Partners Limited acted as advisor to DeepVerge plc.
Tony Ryan and Michael Fitzgerald, Current management and previous owners of Glanaco completed the acquisition of Glanaco Limited from DeepVerge plc (AIM:DVRG) on August 7, 2023. Annuncio • Aug 01
Deepverge plc Announces Change in Company Secretary DeepVerge plc announced Fiona Joyce has resigned as Company Secretary. Nigel Burton will be appointed to fulfil this role. Annuncio • Feb 07
DeepVerge plc Announces Board Change DeepVerge plc announced change to the board and to the role undertaken by an existing director. Fionan Murray has stepped down from the board with immediate effect to concentrate during his notice period on maximising the value of Skin Trust Club and Labskin Division, in line with the announcement on 20 July 2022 that the Company is exploring a range of options to meet the unprecedented demand for Labskin services and the accelerating growth of Skin Trust Club. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Chairman Ross Martin Hilton Andrews was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Nov 07
DeepVerge plc Announces Management Changes DeepVerge plc announced that further to the announcements of 25 October 2022 and 3 November 2022, Gerard Brandon, executive director with responsibility for the Modern Water Division, has resigned and will leave the company with immediate effect to enable him to devote more time to his other business commitments. Gerry joined the company in August 2018 and has led the transformation of the business from a purely non-animal-testing, skin care and cosmetics business to anenvironmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins, doubling turnover every year from £0.27m in 2018 to £9.3m in 2021, with a forecast of £18m in 2022. The company announced the appointment of Paul Ryan as General Manager of the Modern Water division reporting directly to Fionan Murray. Paul is currently the company's chief Business Development Officer and has played a key role in transitioning Modern Water to a solutions business. He has a background in business development in emerging markets and is an experienced senior executive who has built 'tier one' distribution channels globally for over 20 years by developing relationships with utilities, national and municipal governments. He understands equipment, software and AI, and has played a leadership role in leveraging the Group's skills in instrumentation, software and data to create big ticket smart solutions that have been and are being installed and referenced in Modern Water's markets. His relationships with its suppliers, partners and customers make Paul ideally qualified for his new role. Reported Earnings • Sep 23
First half 2022 earnings released: UK£0.01 loss per share (vs UK£0.014 loss in 1H 2021) First half 2022 results: UK£0.01 loss per share (improved from UK£0.014 loss in 1H 2021). Revenue: UK£6.44m (up 94% from 1H 2021). Net loss: UK£2.22m (loss narrowed 9.0% from 1H 2021). Annuncio • Sep 22
DeepVerge plc Reaffirms Sales Guidance for the Financial Year 2022 DeepVerge plc announced that as previously notified, with £18 million in sales expected for the full financial year. Reported Earnings • Jun 24
Full year 2021 earnings released Full year 2021 results: Revenue: UK£9.30m (up 107% from FY 2020). Net loss: UK£2.68m (loss narrowed 1.4% from FY 2020). Board Change • Apr 29
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Chairman Ross Martin Hilton Andrews was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Mar 29
DeepVerge plc Announces Installation of Microtox®Pd Systems DeepVerge plc announced that Optimer-enabled Microtox®PD systems for the detection of pathogens in wastewater have been installed at six sites across the UK as part of the Environmental Monitoring for Health Protection (EMHP) programme, with further installations expected in the UK over the next few months as part of the programme. MicrotoxPD from DeepVerge offers real-time detection and monitoring of pathogens in wastewater and drinking water. This system relies on specific Optimer binders to pathogen targets of interest, coated on sensing chips within the units,to detect and monitor SARS-CoV-2 in wastewater. The SARS-CoV-2 Optimer binders were developed using the Company's proprietary discovery and development platform, with scalable manufacture to support the increased demand for sensors as more MicrotoxPD systems are deployed. Aptamer Group was selected as the preferred affinity ligand supplier for MicrotoxPD following performance evaluation of the SARS-CoV-2 Optimers in parallel with ligands from different suppliers. An agreed extension of this partnership will see further Optimer binders developed for Influenza A, Influenza B, Polio and Pepper Mild Mottle Virus in wastewater and E.coli in drinking water to further expand the detection capabilities of the MicrotoxPD system. The EMHP programme for wastewater monitoring is led by the Joint Biosecurity Centre (which forms part of NHS Test & Trace), DEFRA, academics and water companies. Data received from the MircotoxPD units under the programme will allow public health bodies to offer targeted containment in response to developing disease outbreaks, and identification of the SARS-CoV-2 variants of concern, each of which Aptamer's SARS-CoV-2 binder is able to detect. Annuncio • Jan 19
DeepVerge plc Confirms That Analysis to Investigate the Detection of Sars-Cov-2 Virus on Microtox®Pd Chips Coated with Optimers Binding Agents DeepVerge plc confirmed that analysis to investigate the detection of SARS-CoV-2 virus on Microtox®PD chips coated with Optimers[i], binding agents provided by Aptamer Group plc has detected 3 common variants of concern of SARS-CoV-2 virus. Modern Water Mobile Services[ii] (RNS December 10, 2021), due to launch later this quarter, will have Compact Microtox®PD units with the ability to test for all 3 variants to detect and quantify the spready of COVID-19 in the community. Scientists at the York, UK, Laboratory, have successfully populated the binding agents on the chips using an anti-SARS-CoV-2 antibody, that was raised against the Alpha variant. While variation of detection of all 3 variants was observed, both Delta and Omicron variants had a higher affinity to the Optimer coated chips than Alpha. The Company believes these results validate the expansion of the York facilities to accommodate containment level 3 to work on dangerous pathogens, which include SARS-CoV-2. Reported Earnings • Sep 17
First half 2021 earnings released: UK£0.014 loss per share (vs UK£0.009 loss in 1H 2020) The company reported a solid first half result with improved revenues and control over costs, although losses increased. First half 2021 results: Revenue: UK£3.32m (up 231% from 1H 2020). Net loss: UK£2.44m (loss widened 164% from 1H 2020). Reported Earnings • Jul 03
Full year 2020 earnings released: UK£0.021 loss per share (vs UK£0.028 loss in FY 2019) The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: UK£4.48m (up 445% from FY 2019). Net loss: UK£2.72m (loss widened 20% from FY 2019). Annuncio • Jul 03
DeepVerge plc Provides Revenue Guidance for Fiscal Year 2021 DeepVerge plc announced that for Fiscal Year 2021 revenue guidance remains at £10 million with £3.6 million already received in Modern Water First Quarter orders. Annuncio • Jun 25
DeepVerge plc Announces Microtox PD claims world first live data alerts of SARS-Cov-2 in wastewater treatment plants DeepVerge plc announced the successful completion of Phase 3 field trials in which Microtox® PD achieved real-time detection and transmission of data, specific to SARS-CoV-2, in wastewater treatment plants at multiple sites. As a result, its Environmental Health Division ("Modern Water") has entered into a master service agreement with EPS Group to install, calibrate, service and maintain Microtox®PD units which, subject to negotiation with undisclosed parties, have the potential to be installed in multiple European countries. On the 24 September 2020, the Company announced completion of the integration of an Affimer/Aptamer-based real-time SARS-CoV-2 detector and alert system into Modern Water's Microtox water contamination system, now called Microtox® PD, for the detection of the coronavirus in wastewater. Microtox® PD successfully completed initial spike protein testing and validation of SARS-CoV-2 in filtered wastewater and transitioned to the University of Aberdeen for full beta testing of the system using real SARS-CoV-2 virus samples in its containment level 3 laboratory, prior to initiation of the field trials, referred to above. Annuncio • Jun 09
DeepVerge plc has completed a Follow-on Equity Offering in the amount of £10 million. DeepVerge plc has completed a Follow-on Equity Offering in the amount of £10 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 33,333,334
Price\Range: £0.3
Transaction Features: Regulation S; Subsequent Direct Listing Annuncio • Apr 27
DeepVerge Announces the Skin Trust Club DeepVerge announced the Skin Trust Club, iOS Apple app is now available in the App Store for download in UK and Ireland. The world's first personalised beauty experience that analyses each user's unique skin microbiome to offer a detailed skin routine in a way that has not been possible before. The Skin Trust Club (www.skintrustclub.com) offers customised skincare routine derived from a home test kit, lab tested and linked to the subscriber's local environment via a smartphone App that identifies ingredients suited to the subscriber's unique skin microbiome and provides updates in real-time. A new revolutionary approach to individual skin maintenance through personalised skincare routine. Home Test Kit comprises a single swab that maps the skin microbiome delivering a report that produces the most appropriate daily skincare routine based on science, not guesswork. Using real-time air pollution and weather data from the customer's location, the Skin Trust App builds a complete picture of the skin microbiome and the impact of local surroundings. Recent Insider Transactions • Apr 15
Independent Chairman recently bought €58k worth of stock On the 12th of April, Ross Martin Hilton Andrews bought around 150k shares on-market at roughly €0.39 per share. This was the largest purchase by an insider in the last 3 months. This was Ross Martin Hilton's only on-market trade for the last 12 months. Annuncio • Mar 17
DeepVerge Announces Initial Data for Ongoing Phase III Clinical Studies on the Detection of SARS-CoV-2 on Breath Samples and Identification of Confirmed COVID19 Positive Patients DeepVerge announced initial data for ongoing Phase III clinical studies on the detection of SARS-CoV-2 on breath samples and identification of confirmed COVID19 positive patients. Since third quarter 2020, DeepVerge scientists have been working under laboratory conditions with the Spike Protein ("S-Protein") of SARS-CoV-2 on the SARS-CoV-2 virus inside the Containment Level 3 ("CL3") laboratories at the University of Aberdeen. In these studies, they have detected and identified the virus S-Protein in quantities at 40 femtogram[i] per millilitre ("Fg/mL") at close to 100% sensitivity and specificity on DeepVerge's Microtox® BT[ii] nano-optofluidic chip. In addition, under the clinical trial supervision of the Royal College of Surgeons, Ireland, 40 subjects, 16 of which were independently confirmed as COVID19 positive with PCR[iii] tests, provided breath samples that were tested on the Microtox® BT nano-optofluidic chip surface with Affimer® reagents ("Avacta Group")[iv] and Optimers ("Aptamer Group")[v] together the ("Binding Agents"). The breath samples detected binding on the nano-optofluidic chip with a secondary antibody to the Spike Protein which was initially selected for the isolated spike protein work. Detection of the live virus was confirmed indicating 9 times increase in the digital spectrum signal on the Microtox® BT when compared to controls of nano-optofluidic chips with binding agent; and 19 times increase in signal with nano-optofluidic chips without binding agents. Additional digital background noise was indicated due to the non-specific binding of the antibody. Further data is required to confirm the same high sensitivity and specificity is achieved on breath test clinical trials which are underway. Annuncio • Feb 18
Deepverge Announces Production Orders Worth USD 5 Million for Modern Water Equipment in First Quarter DeepVerge announced that since the offer for the acquisition of Modern Water plc was completed on November 17, 2020, contractual obligations have been signed for the production of water contamination equipment worth USD 5 million (£3.6 million) to meet its obligations with distributors and customers. Notably, 80% of the equipment being produced is earmarked for the Chinese market, where further assembly and localization will be carried out. These orders are expected to be delivered during the current financial year ending 31 December 2021. Annuncio • Feb 16
DeepVerge Signs Heads of Terms with Microsaic Systems plc for Sales, Marketing and Distribution of Microsaic Equipment and Technology Through Deepverge Global Distributor Network DeepVerge announced that it has signed a non-binding Heads of Terms with Microsaic Systems plc to enter a multi-year Framework Services Agreement ("Agreement") whereby DeepVerge will be appointed as non-exclusive agent to promote Microsaic's technologies. The Agreement, to be completed on or before the 31 March 2021, will allow for the supply of miniaturised mass spectrometry contamination detection equipment and services across DeepVerge's network of sales, marketing and distribution channels in laboratory, chemical, biochemical, biofuel and biodegradable plastic and waste-water treatment industries. The Heads of Terms include provision for an initial order for two units, each worth £50,000, plus up to £150,000 commitment by DeepVerge to install pilot facilities located in the recently announced 2021 expansion of DeepVerge York, UK laboratories. Under the Agreement it is expected that Microsaic shall pay to DeepVerge an agency commission based on the revenues received from customers introduced by DeepVerge. The Agreement is expected to have an initial period of three years. As non executive directors of Microsaic, Gerard Brandon and Nigel Burton abstained from participating in DeepVerge's board consideration of the Heads of Terms and decision to proceed to signature of the Heads of Terms. DeepVerge notes that Microsaic will also be joining the EcoWaterOS Consortium, an end-to-end water contamination detection and decontamination solutions provider network, for real-time monitoring and detection of contaminated water. Recent Insider Transactions • Feb 10
CEO & Director recently sold €71k worth of stock On the 4th of February, Gerard Brandon sold around 195k shares on-market at roughly €0.37 per share. This was the largest sale by an insider in the last 3 months. Gerard has been a seller over the last 12 months, reducing personal holdings by €38k. Annuncio • Dec 13
DeepVerge Announces New R&D Service DeepVerge announced a new R&D service, launched in August 2020, has already generated £400,000 in completed sales in Fourth Quarter with agreements with 10 new clients that had previously not used Labskin services. These agreements include framework Master Services Agreements with 2 of the world's large suppliers of consumer products related to skincare. The new service, designed to quickly validate the impact of ingredients such as probiotics and prebiotics on the skin microbiome, clones the human skin microbiome using six microbial strains and delivers real world environment results that mirror the impact of treatments and therapeutics on real human skin. The new R&D service adds to the existing client offering. It increases revenue per client and delivers higher value test services on ingredients used in an expansive range of products - from anti-viral, to shampoos to babies' nappies. The new service replicates skin conditions of the scalp, face, mouth and abdomen. It also utilises AI which has significantly improved the speed and accuracy of testing ingredients on virtual skin models. Annuncio • Nov 16
DeepVerge Announces Update on Detection of Covid-19 Products DeepVerge has commenced deployment of near-source wastewater contamination test equipment ("Microtox PD") into water treatment plants in Ireland, with first shipments to China and the US expected by year-end. Microtox PD units, retrofitted with AI based optofluidic pathogen identification scanners, are also being shipped to the University of Aberdeen CAT3 laboratory, adding to the ongoing trials with the live SARS-CoV-2, supplied by Public Health England. In addition, DeepVerge has agreed to license a patented breathalyser from PulMoBioMed Limited ("PBM"), a spin-out technology company of Northumbria University, to capture SARS-CoV-2 particles in breath condensate for the DeepVerge optofluidic breath test ("Microtox BT").Phase 3 field trials are expected to begin shortly at multiple sites in Northern England. In collaboration with EcoWaterOS consortia partners, aggregated anonymised data will provide datasets for AI model simulations from human volunteers who will undergo COVID-19 testing with a combination of Microtox BT, a lateral flow antigen test and a rt-PCR test. Sufficient datasets are anticipated to be complete early in 2021. Annuncio • Nov 12
DeepVerge plc Appoints Nigel Burton as Non-Executive Director DeepVerge plc announced the appointment of Dr. Nigel Burton as a Non-Executive Director with effect from 10 November 2020. Nigel is a Non-Executive Director of Modern Water plc.